Global Autism Disorder Treatment Market Opportunities and Forecast 2020-2027

1 Report Prologue 12

2 Market Introduction 16

• 2.1 Scope of Study 17
• 2.2 Research Objective 17
• 2.3 Assumptions & Limitations 17
  • 2.3.1 Assumptions 17
  • 2.3.2 Limitations 17

3 Research Methodology 18

• 3.1 Primary Research Methodology 19
• 3.2 Secondary Research Methodology 20
• 3.3 Market Share Analysis 21
• 3.4 Trade Analysis 21
• 3.5 Market Pricing Approach 21

4 Market Dynamics 22

• 4.1 Introduction 23
• 4.2 Drivers 24
  • 4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD) 24
  • 4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth 25
  • 4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease 26
• 4.3 Restraints 27
  • 4.3.1 Weak Product Pipeline of First Drugs for Autism 27
  • 4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options 28
• 4.4 Opportunities 29
  • 4.4.1 Rising Investments by Venture Non-Pharmacology Activities 29
• 4.5 Mega Trends: 30
• 4.6 Macroeconomic Indicators 30

5 Market Factor Analysis 31

• 5.1 Porter’s Five Forces Model 32
  • 5.1.1 Bargaining Power of Suppliers 33
  • 5.1.2 Bargaining Power of Buyers 33
  • 5.1.3 Threat of New Entrants 33
  • 5.1.4 Threat of Substitutes 33
  • 5.1.5 Intensity of Rivalry 33
• 5.2 Value Chain Analysis 34
  • 5.2.1 R&D 34
  • 5.2.2 Manufacturing 34
  • 5.2.3 Distribution & Sales 34
  • 5.2.4 Post-Sales Monitoring 35
• 5.3 Pricing Analysis 36
• 5.4 Investment Opportunity Analysis 36
• 5.5 Demand & Supply: Gap Analysis 36

6 Global Autism Disorder & Treatment Market, By Type 38

• 6.1 Introduction 39
• 6.2 Asperger Syndrome 40
• 6.3 Pervasive Developmental Disorders (PDDs) 40

7 Global Autism Disorder & Treatment Market, By Treatment Type 41

• 7.1 Introduction 42
• 7.2 Expert Opinion: Oxytocin 42
• 7.3 ABA (applied behavioral analysis) 43
• 7.4 Hyperbaric oxygen therapy 44
• 7.5 Chelation therapy 44
• 7.6 Oxytocin therapy 44

8 Global Autism Disorder & Treatment Market, By Drugs 45

• 8.1 Introduction 46
• 8.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 47
• 8.3 Anti-convulsants 48
• 8.4 Stimulants 48
• 8.5 Anti-psychotic 48

9 Global Autism Disorder & Treatment Market, By Region 49

• 9.1 Introduction 50
• 9.2 Americas 51
• 9.3 North America 54
  • 9.3.1 U.S. 54
• 9.4 Canada 55
  • 9.4.1 South America 56
• 9.5 Europe 57
  • 9.5.1 Germany 60
  • 9.5.2 France 61
  • 9.5.3 UK 62
  • 9.5.4 Italy 63
  • 9.5.5 Spain 64
  • 9.5.6 Rest of Western Europe 65
  • 9.5.7 Eastern Europe 66
• 9.6 Asia Pacific 67
  • 9.6.1 Japan 69
  • 9.6.2 China 70
  • 9.6.3 India 71
  • 9.6.4 Australia 72
  • 9.6.5 Republic of Korea 73
  • 9.6.6 Rest of Asia Pacific 74
• 9.7 Middle East & Africa 76
  • 9.7.1 UAE 78
  • 9.7.2 Saudi Arabia 79
  • 9.7.3 Oman 80
  • 9.7.4 Kuwait 81
  • 9.7.5 Qatar 82
  • 9.7.6 Rest of Middle East & Africa 83

10 Competitive Landscape 85

• 10.1 Company Market Share Analysis 86
  • 10.1.1 Introduction 86
• 10.2 Competitive Landscape 87
  • 10.2.1 Introduction 87
• 10.3 Recent Developments, 2013-2018 88

11 Company Profiles 90

• 11.1 Pfizer Inc. 91
  • 11.1.1 Company Overview 91
  • 11.1.2 Financials 91
  • 11.1.3 Products 91
  • 11.1.4 Strategy 91
  • 11.1.5 Key Developments 91
• 11.2 Allergan, Plc 92
  • 11.2.1 Company Overview 92
  • 11.2.2 Financials 92
  • 11.2.3 Products 92
  • 11.2.4 Strategy 92
  • 11.2.5 Key Developments 92
• 11.3 Eli Lilly and Company 93
  • 11.3.1 Company Overview 93
  • 11.3.2 Financials 93
  • 11.3.3 Products 93
  • 11.3.4 Strategy 93
  • 11.3.5 Key Developments 93
• 11.4 Bristol-Myers Squibb Company 94
  • 11.4.1 Company Overview 94
  • 11.4.2 Financials 94
  • 11.4.3 Products 94
  • 11.4.4 Strategy 94
  • 11.4.5 Key Developments 94
• 11.5 Sun Pharmaceutical Industries Ltd. 95
  • 11.5.1 Company Overview 95
  • 11.5.2 Financials 95
  • 11.5.3 Products 95
  • 11.5.4 Strategy 95
  • 11.5.5 Key Developments 95
• 11.6 Johnson & Johnson Services, Inc. 96
  • 11.6.1 Company Overview 96
  • 11.6.2 Financials 96
  • 11.6.3 Products 96
  • 11.6.4 Strategy 96
  • 11.6.5 Key Developments 96
• 11.7 Teva Pharmaceutical Industries Ltd. 97
  • 11.7.1 Company Overview 97
  • 11.7.2 Financials 97
  • 11.7.3 Products 97
  • 11.7.4 Strategy 97
  • 11.7.5 Key Developments 97
• 11.8 Merck & Co. Inc 98
  • 11.8.1 Company Overview 98
  • 11.8.2 Financials 98
  • 11.8.3 Products 98
  • 11.8.4 Strategy 98
  • 11.8.5 Key Developments 98
• 11.9 Novartis AG 99
  • 11.9.1 Company Overview 99
  • 11.9.2 Financials 99
  • 11.9.3 Products 99
  • 11.9.4 Strategy 99
  • 11.9.5 Key Developments 99
• 11.10 Otsuka Holdings Co. Ltd 100
  • 11.10.1 Company Overview 100
  • 11.10.2 Financials 100
  • 11.10.3 Products 100
  • 11.10.4 Strategy 100
  • 11.10.5 Key Developments 100
• 11.11 Consern Pharma Private Limited 101

12 Conclusion 102

• 12.1 Key Findings 103
  • 12.1.1 CEO’s Viewpoint 103
  • 12.1.2 Key Companies to Watch 103
  • 12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry 103

13 Appendix 104

• 13.1 Discussion Blue Print 105
• 13.2 Expert Opinion: Oxytocin 107
• 13.3 References 107